4D Molecular Therapeutics (FDMT)
US Market

4D Molecular Therapeutics (FDMT) Financial Statements


4D Molecular Therapeutics Financial Overview

4D Molecular Therapeutics's market cap is currently ―. The company's EPS TTM is $-3.381; its P/E ratio is -5.43; 4D Molecular Therapeutics is scheduled to report earnings on August 10, 2023, and the estimated EPS forecast is $-0.80. See an overview of income statement, balance sheet, and cash flow financials.
Mar 23Dec 22Sep 22Jun 22Mar 22
Income Statement-
Total Revenue$ 298.00K$ 1.25M$ 500.00K$ 162.00K$ 1.22M
Gross Profit$ 298.00K$ 1.25M---
EBIT$ -30.13M$ -28.72M$ -26.50M$ -28.43M$ -26.39M
EBITDA$ -29.11M$ -27.56M$ -25.62M$ -27.59M$ -25.61M
Net Income Common Stockholders$ -28.68M$ -27.38M$ -25.69M$ -28.09M$ -26.34M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 200.45M$ 213.55M$ 227.72M$ 241.09M$ 236.15M
Total Assets$ 244.02M$ 261.85M$ 280.16M$ 302.94M$ 324.93M
Total Debt$ 15.68M$ 16.12M$ 16.55M$ 17.00M$ 16.82M
Net Debt$ -184.77M$ -197.43M$ -211.16M$ -224.09M$ -219.33M
Total Liabilities$ 25.41M$ 30.51M$ 28.72M$ 30.42M$ 28.87M
Stockholders Equity$ 218.61M$ 231.34M$ 251.44M$ 272.52M$ 296.06M
Cash Flow-
Free Cash Flow$ -28.92M$ -23.31M$ -22.98M$ -21.97M$ -29.96M
Operating Cash Flow$ -27.91M$ -22.21M$ -21.02M$ -19.90M$ -23.55M
Investing Cash Flow$ 43.13M$ -35.78M$ 15.37M$ 57.47M$ -54.11M
Financing Cash Flow$ 10.99M$ 2.05M$ 460.00K$ -50.00K$ 629.00K
Currency in USD

4D Molecular Therapeutics Earnings and Revenue History

4D Molecular Therapeutics Debt to Assets

4D Molecular Therapeutics Cash Flow

4D Molecular Therapeutics Forecast EPS vs Actual EPS

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis